Psoriatic Arthritis News

Adult patients with active psoriatic arthritis who received risankizumab reported sustained improvements in skin and joint symptoms at week 100 in two ongoing phase 3 trials, according to data released by AbbVie.

The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

Patients with psoriatic arthritis may consider tapering once treatment goals are reached, according to guidance from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis published in Nature Reviews Rheumatology.

For patients with psoriatic arthritis, collaboration between a dermatologist and rheumatologist is integral to receiving optimal care.

Guselkumab demonstrates sustained benefits for multiple, diverse manifestations of psoriatic arthritis through 1 year, according to data published in Rheumatology.

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

For patients with psoriasis, tools such as the Psoriasis Epidemiology Screening Tool can help predict the possibility of future psoriatic arthritis development, according to a study.

Addressing the racial disparities that continue to plague health care requires “continuous” work, as well as holding certain providers’ “feet to the fire,” said a presenter at the 2022 Association of Women in Rheumatology annual conference.

Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.